Market Research Logo

Vernalis Plc - Product Pipeline Review - 2015

Vernalis Plc - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Vernalis plc - Product Pipeline Review - 2015’, provides an overview of the Vernalis plc’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vernalis plc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vernalis plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vernalis plc’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vernalis plc’s pipeline products
Reasons to buy
  • Evaluate Vernalis plc’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vernalis plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vernalis plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vernalis plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vernalis plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vernalis plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Vernalis Plc Snapshot
Vernalis Plc Overview
Key Information
Key Facts
Vernalis Plc - Research and Development Overview
Key Therapeutic Areas
Vernalis Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Vernalis Plc - Pipeline Products Glance
Vernalis Plc - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Vernalis Plc - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Vernalis Plc - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
Vernalis Plc - Drug Profiles
V-81444
Product Description
Mechanism of Action
R&D Progress
CCP-05
Product Description
Mechanism of Action
R&D Progress
CCP-06
Product Description
Mechanism of Action
R&D Progress
V-158411
Product Description
Mechanism of Action
R&D Progress
vipadenant
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Chk1 for Cancer
Product Description
Mechanism of Action
R&D Progress
CCP-07
Product Description
Mechanism of Action
R&D Progress
CCP-08
Product Description
Mechanism of Action
R&D Progress
Vernalis Plc - Pipeline Analysis
Vernalis Plc - Pipeline Products by Target
Vernalis Plc - Pipeline Products by Route of Administration
Vernalis Plc - Pipeline Products by Molecule Type
Vernalis Plc - Pipeline Products by Mechanism of Action
Vernalis Plc - Recent Pipeline Updates
Vernalis Plc - Dormant Projects
Vernalis Plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
alfadolone
indantadol
marimastat
solimastat
V-1003
V-158866
vipadenant
Vernalis Plc - Company Statement
Vernalis Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Vernalis Plc, Key Information
Vernalis Plc, Key Facts
Vernalis Plc - Pipeline by Indication, 2015
Vernalis Plc - Pipeline by Stage of Development, 2015
Vernalis Plc - Monotherapy Products in Pipeline, 2015
Vernalis Plc - Partnered Products in Pipeline, 2015
Vernalis Plc - Partnered Products/ Combination Treatment Modalities, 2015
Vernalis Plc - Out-Licensed Products in Pipeline, 2015
Vernalis Plc - Out-Licensed Products/ Combination Treatment Modalities, 2015
Vernalis Plc - Phase II, 2015
Vernalis Plc - Preclinical, 2015
Vernalis Plc - Discovery, 2015
Vernalis Plc - Unknown, 2015
Vernalis Plc - Pipeline by Target, 2015
Vernalis Plc - Pipeline by Route of Administration, 2015
Vernalis Plc - Pipeline by Molecule Type, 2015
Vernalis Plc - Pipeline Products by Mechanism of Action, 2015
Vernalis Plc - Recent Pipeline Updates, 2015
Vernalis Plc - Dormant Developmental Projects,2015
Vernalis Plc - Discontinued Pipeline Products, 2015
Vernalis Plc, Subsidiaries
List of Figures
Vernalis Plc - Pipeline by Top 10 Indication, 2015
Vernalis Plc - Pipeline by Stage of Development, 2015
Vernalis Plc - Monotherapy Products in Pipeline, 2015
Vernalis Plc - Partnered Products in Pipeline, 2015
Vernalis Plc - Out-Licensed Products in Pipeline, 2015
Vernalis Plc - Pipeline by Top 10 Target, 2015
Vernalis Plc - Pipeline by Top 10 Route of Administration, 2015
Vernalis Plc - Pipeline by Top 10 Molecule Type, 2015
Vernalis Plc - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report